Antenatal prophylaxis of Rh isoimmunization: 28-weeks'-gestation service program

Two (0.18%) of 1086 Rh-negative primigravidas or multigravidas treated similarly in all previous pregnancies, who were given a single injection of Rh immune globulin (300 μg) at 28 weeks'' gestation and subsequently were delivered of Rh-positive babies, had demonstrable Rh isoimmunization at the time of that injection and must be considered “logistic” failures of antenatal prophylaxis. The remaining 1084 (who were treated again after delivery) had no evidence of Rh isoimmunization at delivery and none of the 512 screened at 6 months after delivery appeared to be immunized. If the 28th-week injection had not been protective, one would have expected 14 of the 1084 to have been demonstrably Rh isoimmunized and evidence of Rh isoimmunization to have persisted in 6 of the 512 observed 6 months after delivery.Six of 719 Rh-negative multigravidas who had not received Rh immune globulin after previous pregnancies or had been treated only after delivery showed evidence of Rh isoimmunization despite a single injection of Rh immune globulin at 28 weeks in a subsequent pregnancy. In three of the six the cause was most likely “sensibilization” due to previous exposure to Rh-positive blood or an untreated Rh-positive pregnancy. in 3 of the remaining 716 (0.42%) there may have been true failure of antenatal Rh prophylaxis administered at the 28th week. One would have expected this figure to be 12 of 716 if antenatal Rh prophylaxis at 28 weeks'' gestation were totally unsuccessful.It is concluded that a single intramuscular injection of Rh immune globulin, 300 μg, is 88% effective in preventing Rh isoimmunization during pregnancy in Rh-negative primigravidas and in multigravidas treated antenatally in all previous pregnancies, and is 75% effective in preventing Rh isoimmunization in Rh-negative multigravidas untreated during previous pregnancies. The majority of failures are due to Rh isoimmunization during pregnancy prior to antenatal prophylaxis at 28 weeks.     

Fractionated Therapy of HER2-Expressing Breast and Ovarian Cancer Xenografts in Mice with Targeted Alpha Emitting (227)Th-DOTA-p-benzyl-trastuzumab

Background

The aim of this study was to investigate therapeutic efficacy and normal tissue toxicity of single dosage and fractionated targeted alpha therapy (TAT) in mice with HER2-expressing breast and ovarian cancer xenografts using the low dose rate radioimmunoconjugate ²²⁷Th-DOTA-p-benzyl-trastuzumab.

Methodology/Principal Findings

Nude mice carrying HER2-overexpressing subcutaneous SKOV-3 or SKBR-3 xenografts were treated with 1000 kBq/kg ²²⁷Th-trastuzumab as single injection or four injections of 250 kBq/kg with intervals of 4–5 days, 2 weeks, or 4 weeks. Control animals were treated with normal saline or unlabeled trastuzumab. In SKOV-3 xenografts tumor growth to 10-fold size was delayed (p<0.01) and survival with tumor diameter less than 16 mm was prolonged (p<0.05) in all TAT groups compared to the control groups. No statistically significant differences were seen among the treated groups. In SKBR-3 xenografts tumor growth to 10-fold size was delayed in the single injection and 4–5 days interval groups (p<0.001) and all except the 4 weeks interval TAT group showed improved survival to the control groups (p<0.05). Toxicity was assessed by blood cell counts, clinical chemistry measurements and body weight. Transient reduction in white blood cells was seen for the single injection and 4–5 days interval groups (p<0.05). No significant changes were seen in red blood cells, platelets or clinical chemistry parameters. Survival without life threatening loss of body weight was significantly prolonged in 4 weeks interval group compared to single injection group (p<0.05) for SKOV-3 animals and in 2 weeks interval group compared with the 4–5 days interval groups (p<0.05) for SKBR-3 animals.

Conclusions/Significance

The same concentration of radioactivity split into several fractions may improve toxicity of ²²⁷Th-radioimmunotherapy while the therapeutic effect is maintained. Thus, it might be possible to increase the cumulative absorbed radiation dose to tumor with acceptable toxicity by fractionation of the dosage.     

Early cycle FSH-p priming as a prelude to superovulating gonadotropin administration in ewes and heifers

The effect of an exogenous FSH treatment in the periovulatory, post-LH surge period on superovulatory response in the subsequent cycle of ewes and heifers was investigated. Thirty-five ewes were synchronized with progestagen pessaries and pregnant mares serum gonadotropin. The day following the onset of estrus (Day 1) 17 ewes received one intramuscular injection of 5 mg follicle stimulating hormone of porcine origin (FSH-p). All 35 ewes received another progestagen pessary on Day 1 and were superovulated with horse anterior pituitary extract (HAP). The ewes were bred and embryos collected 6 days following the onset of estrus. Early cycle FSH-p administration did not increase the subsequent ovulation rate (6.5 vs. 8.4 for controls, n.s.). Recovery rate for the FSH-p treated animals was higher (78.5% vs. 49.3%; P<0.05) as was fertilization rate (100% vs. 62.4%; P<0.05). The final result was a mean of 4.4 transferable embryos per ewe treated among the FSH-p boosted ewes and 2.6 transferable embryos per ewe treated among the control ewes.Twenty-nine heifers were brought into estrus with one 500-μg injection of prostaglandin F_2α (PG). Twelve of the 29 heifers were given one intramuscular injection of 10 mg FSH-p on either Day 2 or 3 (Day 1 is the day following the onset of estrus). All heifers were superovulated starting on Day 11–16, over a 4-day period using a decreasing dosage of FSH-p. Prostaglandin was administered at the time of the fifth superovulatory FSH-p injection and the heifers were bred by artificial insemination. Ova were recovered between 2 and 4.5 days following the onset of estrus. There was no effect on ovulation rate due to the interval from FSH-p priming to the day of superovulatory FSH-p initiation. The proportion of heifers that ovulated when given a FSH-p injection early in the cycle was higher than in the control group (94% vs. 68%; P<0.05). The primed heifers had a higher number of ovulations than did the control heifers (16.3 vs. 6.2; P<0.01). The effect of higher ovulation rate carried through all parameters measured, so that the FSH-p primed heifers also had a higher number of fertilized ova than the controls (10.7 vs. 3.9; P<0.05), indicating that there was no significant deterioration in ovum quality due to the FSH-p priming. The results show that FSH-p improved superovulatory efficiency in both sheep and cattle.     

Renal Effects of Calcitonin

Porcine calcitonin in a slow-release gelatin vehicle was given by intramuscular injection to 10 patients—four with primary hyperparathyroidism, four with Paget''s disease, and two with carcinoma of the breast and hypercalcaemia. All cases showed a fall in serum calcium with an immediate rise in urine calcium. All except three patients with primary hyperparathyroidism showed a fall in serum phosphorus, but an immediate rise in urine phosphorus occurred in all cases. Urine hydroxyproline output fell in three patients with severe Paget''s disease. Urine sodium rose in all cases, but the effects on potassium, magnesium, water, and pH were not appreciably different from results obtained in four control subjects who were given the gelatin vehicle alone.The data suggest that calcitonin caused a decrease in the tubular resorption of calcium and phosphorus. The hypocalcaemic effect appeared to be due to a decrease in bone resorption in the patients with Paget''s disease but in the remaining cases could be accounted for in part or entirely by the rise in urine calcium.     

Superovulation of Holstein heifers by a single subcutaneous injection of FSH dissolved in polyvinylpyrrolidone

This study was undertaken to determine whether a single injection of porcine FSH (pFSH) would induce a superovulatory response in cattle. Holstein heifers were given a single injection of pFSH (30 mg, s.c.) dissolved in saline (Group 1, n = 5); 50% polyvinylpyrrolidone (PVP; Group 2, n = 5); or 25% PVP (Group 3, n = 4). Group-4 heifers (n = 5) were given multiple intramuscular injections of pFSH every 12 h for 3 d at decreasing doses, for a total of 30 mg. All animals received a single injection of 750 microg PGF2 alpha 48 h after the initiation of pFSH treatment. Animals exhibiting estrus were artificially inseminated twice throughout estrus. Ova and embryos were recovered nonsurgically. Ovaries were examined by transrectal ultrasonography or by palpation per rectum on Day 7 or 8 of estrus. Plasma concentrations of pFSH, bovine FSH progesterone, estradiol-17 beta and inhibin were determined by specific radioimmunoassays. The number of corpora lutea (CL) and the numbers of total and transferable embryos which were detected and recovered in Groups 2 and 3 were equivalent to the numbers detected and recovered in Group 4. In Group 1, however, only 1 of 5 animals ovulated even a single oocyte. The present study demonstrated that only a single injection of pFSH dissolved in PVP was capable of inducing a superovulatory response by maintaining a high plasma FSH concentration to allow for the recovery of a sufficient number of embryos for transplantation.     

The Disappearance Rate in Reindeer of Famphur an Organophosphorus Parasiticide

The present investigations were carried out in order to study the disappearance rate in reindeer of famphur (0,O-dimethyl-O,p-(NtN-di-methylsulphamoyl) phenyl phosphorothioate), a promising systemic parasiticide for the control of reindeer warble and nostril flies. The compound was administered intramuscularly to reindeer as a single dose (in the form of the preparation Warbcx). At a dose of 20 mg/kg body weight (2 animals) famphur caused inhibition of plasma and erythrocyte cholinesterase activities by about 50 %. The plasma esterase activity fell off rapidly, within 24 hrs., and returned to normal within 3 weeks, whereas the erythrocyte esterase activity decreased gradually and remained low for at least 4 weeks after dosing. Peak plasma levels of fampliiir, varying between 1 and 16 p.p.m., were attained within 5–33 hrs., after a dose of 30 mg famphur per kg body weight (7 reindeer). The plasma levels declined to below 0.02 p.p.m. in 72–96 hrs. Famoxon, the oxygen analogue of famphur, was observed for 1–2 days in plasma at low levels, amounting to about 10 % of the corresponding famphur levels. In erythrocytes practically no residues were found of either compound. Tissue residue levels were low — except at the injection site. In a series of animals given a dose of 30 mg/kg body weight and killed at varying times after treatment famphur or famoxon were detectable in liver for 4.5 days and in kidney and skeletal muscle remote from the injection site for 12 days. In muscle tissue from the injection site highly variable residue levels were observed, indicating absorption from the intramuscular depot to be erratic. The experimental results suggest that no appreciable consumer hazard would arise from a proposed single-dose intramuscular treatment of reindeer with famphur at a dosage not exceeding 30 mg/kg body weight, provided a minimum interval of 3 weeks is maintained between treatment and slaughter and the muscle tissue around the injection site is discarded.     

Superstimulation of ovarian follicular development in beef cattle with a single intramuscular injection of Folltropin-V

The need to inject FSH twice daily for superstimulation of ovarian follicular development in cattle necessitates frequent attention by farm-personnel and increases the possibility of failures due to mishandling and errors in administration of treatments. A series of three experiments were designed to evaluate the feasibility of superstimulation in beef cattle with a single intramuscular (IM) injection of Folltropin-V diluted in a hyaluronan-based slow-release formulation (SRF). In Experiment 1, cows were assigned to one of three treatment groups to compare two methods of injection as compared to the twice daily IM injection protocol. Superovulatory response of cows (n=6) treated with twice daily IM injections over 4 days (Control) was greater than of cows treated with a single subcutaneous (SC) injection in SRF (n=6), while superovulatory response of cows treated with a single IM injection in SRF (n=6) was intermediate. Experiment 2 was designed to compare two concentrations of SRF (20mg/mL hyaluronan, 100% compared to 10mg/mL hyaluronan, 50%) in a single IM injection protocol. The mean number of corpora lutea (CL) were not significantly different (P≥0.05), but the numbers of total ova/embryos (P<0.05), fertilized ova (P<0.01) and transferable embryos (P<0.001) were greater in cows treated with FSH in 100% SRF (n=20) than cows treated with FSH in 50% SRF (n=20). Experiment 3 was designed to compare superovulatory response in Red Angus donor cows treated with a single IM injection of Folltropin-V diluted in 100% solution of SRF with those treated with the traditional twice-daily IM injection protocol over 4 days. Mean (±SEM) numbers of CL (13.7±1.2 compared to 13.8±1.2), total ova/embryos (12.3±1.5 compared to 13.7±2.1), fertilized ova (7.2±1.1 compared to 8.4±1.4) and transferable embryos (4.9±0.8 compared to 6.4±1.3) were not significantly different between Control (n=29) and Single injection (n=29) groups, respectively. In summary, superstimulation of beef donor cows with a single IM injection of Folltropin-V diluted in 100% solution of SRF resulted in a comparable superovulatory response to the traditional twice-daily IM administration of Folltropin-V diluted in saline over 4 days.     

Pharmacokinetics of long acting oxytetracycline in the laboratory rat

Pharmacokinetic parameters of a slow release form of oxytetracycline were determined in the rat. Triexponential pharmacokinetics were displayed after intravenous administration. The half-life of the distribution phase was 0.097 hours, the rapid elimination half-life was 3.74 hours and the slow elimination half-life was 27.26 hours. Subcutaneous and intramuscular injection resulted in a rapid elimination half-life of 6.09 and 6.02 hours, respectively. In comparison, a standard form of oxytetracycline given subcutaneously had a rapid elimination half-life of 4.22 hours. The slow release form of oxytetracycline has a half-life in the rat long enough to maintain serum levels greater than the minimum inhibitory concentration of Mycoplasma pulmonis with a dose interval of 72 hours.     

Superovulatory response to a single subcutaneous injection of Folltropin-V in beef cattle

A series of 4 experiments were designed to evaluate the feasibility of superstimulation in beef cattle with a single sc injection of the porcine pituitary extract, Folltropin-V. In the preliminary study (Experiment 1), superovulatory response of cows (n=7) treated with a single sc injection of 400 mg NIH-FSH-P1 Folltropin-V was not different than that of cows (n=8) superstimulated with twice daily im injections over 4 d, or a single sc injection plus an injection of eCG (n=12). Experiments 2 and 3 were designed to determine the optimal site of a single sc injection. In Experiment 2, cows (n=25) with body condition scores (BCS) of 1 to 2 were used. The mean number of CL counted and ova/embryos collected was lower (P<0.05) in cows treated with the single sc injection in the neck region than in cows treated with a single sc injection behind the shoulder, or with the twice daily im injection treatment. In Experiment 3, cows (n=49) with BCS of 3 to 5 were used. There were no differences in the number of CL, total ova/embrvos collected, fertilized ova and transferable embryos whether treatments were given in the neck region or behind the shoulder, or whether the cows were implanted or not implanted with Syncro-Mate-B. Experiment 4 was designed to determine the optimal superstimulatory dosage of Folltropin-V administered by a single sc injection. Superovulatory response of cows treated with the higher doses (400 mg, 600 mg or 800 mg NIH-FSH-P1) was higher (P<0.05) than those treated with 200 mg NIH-FSH-P1. The number of unovulated (>/=10 mm) follicles at the time of ova/embryo collection was higher (P<0.05) in the 600 and 800 mg groups, and progesterone concentration at estrus was higher (P<0.05) in cows treated with 800 mg than with 400 or 200 mg. It was concluded that a single, bolus sc injection of 400 mg NIH-FSH-P1 of Folltropin-V is as efficacious as the 4-d, twice daily im treatment protocol for inducing superovulation in beef cows. The amount of subcutaneous fat and site of injection appeared to affect the efficacy of a single sc injection; a single bolus sc injection of Folltropin-V behind the shoulder resulted in the most predictable superovulatory response.     

The Effect of Two Different Oxytetracycline Treatments in Experimental Ehrlichia phagocytophila Infected Lambs

The effect of 2 different oxytetracycline treatments in acute E. phagocytophila infected lambs was investigated. Twenty 5-month-old lambs of the Dala and Rygja breeds were used. Ten lambs were inoculated intravenously with a stabilate of an ovine E. phagocytophila strain. On the third day of fever, 4 lambs were given long-acting oxytetracycline (Terramycin prolongatum vet^?, Pfizer) (20 mg/kg) intramuscularly and another 4 lambs were given short-acting oxytetracycline (Terramycin vet^?, Pfizer) (10 mg/kg) intravenously for 5 consecutive days. The lambs were examined for the presence of Ehrlichia infection by blood smear evaluation, polymerase chain reaction (PCR) and antibody titre against E. equi. One month after the last antibiotic treatment, 250 ml citrate blood from each of these lambs were inoculated into each of 10 susceptible lambs, which were observed during the following 6 weeks. The results indicate that oxytetracycline given in the acute stage of the infection may effectively teminate the development of fever, rickettsemia and weight reduction in E. phagocytophila infected lambs. No difference was observed between the 2 treatment groups. However, at least 3 of 8 antibiotic treated lambs (37.5%) were still infected with granulocytic Ehrlichia 3 months after treatment.     

Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo

We analysed the role of dosage, route and frequency of administration of clinical grade interferon-beta (IFN-beta) preparations in inducing anti-IFN-beta antibodies (IFN-beta-Abs) in 5 groups of relapsing-remitting multiple sclerosis (RRMS) patients who were respectively treated as follows: 1) weekly intramuscular (i.m.) injections of 30 mg of recombinant IFN-beta1a (Avonex), 2) subcutis (s.c.) injections of 250 mg IFN-beta1b (Betaferon) every other day, 3) weekly i.m. injections of 250 mg IFN-beta1b (Betaferon), 4) s.c. injections of 22 mg of IFN-beta1a (Rebif) three times a week, and 5) i.m. injections of 22 mg of IFN-beta1a (Rebif) twice a week. IFN-beta-Abs were determined by ELISA. IFN-beta1b was more immunogenic than IFN-beta1a not only when administered s.c. every other day, but also when administered i.m. at a lower weekly dose; i.m. injection, however, significantly delayed the appearance, and induced lower serum levels of IFN-beta-Abs. In patients treated with s.c. IFN-beta1b, Ab levels peaked 3 to 9 months after therapy initiation, and then slowly, but progressively, declined to pre-therapy levels that in some patients were reached after three years. Patients treated with i.m. or s.c. IFN-beta1a only rarely developed IFN-beta-Abs, and then at very low titers. Overall, the i.m. weekly administration of IFN-beta1a was the less immunogenic treatment. In IFN-beta1b-treated patients, a wash-out period of two/three months was sufficient to bring the IFN-beta-Ab levels below the cut-off. Our findings suggest that the immunogenicity of IFN-beta1a is low, regardless of the route of administration and the dosage, while that of IFN-beta1b is high, and is significantly, but not completely reduced by i.m. administration. As IFN-beta-Abs are cross-reactive, a wash-out period is suggested when the preparation is changed from IFN-beta1b to IFN-beta1a in order to maintain the clinical benefits of the therapy.     

An analysis of mechanical failure of darts and costs involved in drug immobilization of elephant and buffalo

The failure and success achieved while attempting to immobilize sixty-two elephants (Loxodonta africana) and twenty-five African buffalo {Syncerus coffer) with etorphine hydrochloride administered by syringe projectile are described. Failures due to mechanical causes are divided into those occurring before and those occurring after injection. In the elephant series the most frequent cause of mechanical failure before injection was due to the dart bouncing off the target animal often coupled with bending or breaking of the needle. In the buffalo series, misfires due to faulty cartridges were responsible for most of the failures before injection, but bounce-offs were common, too. Failure to immobilize or inadequate immobilization following apparently successful darting of both elephant and buffalo was most often due to the penetration of the plunger by the detonator. A breakdown of the cost of immobilizing forty elephant and twenty buffalo is given. Total costs for each animal successfully immobilized were U. Shs. 323.0 and U. Shs. 359.9 for elephant and buffalo respectively.     

Possibility of reducing the luteolytic dose of cloprostenol in cyclic dairy cows

The administration of cloprostenol by intravulvosubmucous (i.v.s.m.) injection at 1 2 and 1 4 of the dose usually given by intramuscular (i.m.) injection, was tested in dairy cows for luteolysis and estrus synchronization. The i.m. injection was used in ten adult cows at the usual dose of 500 mug/animal. Eleven adult cows and 11 heifers were treated i.v.s.m. with a dose equivalent to 250 mug/animal and 125 mug/animal, respectively. Two injections of cloprostenol were administered 11 days apart to the cows not detected in oestrus after a single injection. Forty-three out of the total 46 animals were detected to be in dioestrus at the time of at least one of the injections, as reflected by the plasma progesterone concentrations at the time of treatments. Three out of the 43 animals injected during dioestrus were refractory to the luteolytic effect of cloprostenol; this appeared to be independent of the dosage and the route of administration (refractory cows were: one adult cow treated i.m. and two treated i.v.s.m. with 125 mug of cloprostenol). The mean time interval from injection to the onset of heat was 82.8 hours with a confidence limit for 95% of probability between 67.9 hours and 92.7 hours. The difference between treatments is not significant. The results suggest that in heifers and adult cows cloprostenol can be given i.v.s.m. route at a reduced dose of 1 4 of the usual 500 mug i.m. dosage without affecting the luteolytic effect of the drug or fertility.     

Induction of Labour in Sheep and in Humans by Single Doses of Corticosteroids

In sheep the administration of single intramuscular injections of dexamethasone into the fetus was shown to be an effective method of initiating parturition. In a controlled trial in women who had gone beyond the 41st week of pregnancy 20 mg betamethasone in saline (six patients) or saline alone (five patients) was injected into the amniotic fluid. In the betamethasone-treated group delivery occurred 78·9 ± 10·2 (S.D.) hours after injection while in the control group it occurred 323 ± 62 (S.D.) hours after injection (P < 0·01). In one woman with an anencephalic pregnancy intra-amniotic injection failed to initiate parturition but delivery occurred 88·5 hours after intramuscular injection of betamethasone into the fetus.     

Chemoprophylaxis with tetracycline drugs in the immunisation of cattle against Theileria annulata infection

Gill B.S., Bhattacharyulu Y., Kaur D. and Singh A. 1978. Chemoprophylaxis with tetracycline drugs in the immunisation of cattle against Theileria annulata infection. International Journal for Parasitology8: 467–469. Three-month-old fully susceptible cross-bred calves were immunised against tropical theileriosis by treating 2-tick or 5-tick stabilate-induced Theileria annulata infections, with 1 or 2 doses of long-acting oxytetracycline (Pfizer) at 20 mg/kg body weight injected subcutaneously, or chlortetracycline at 16 mg/kg body weight daily for 8 days given orally. The treatment began on the day of the infection. After 45 days, the recovered calves were given severe 10-tick homologous stabilate challenge.The reactions were evaluated by noting fever, degree of anaemia, severity of the swelling of the regional lymph node, rate of parasitization of lymphocytes in the lymph node, and of erythrocytes in the peripheral circulation.The untreated calves developed a severe form of the disease with typical symptoms, which killed 1 of 4 and 2 of 5 calves receiving 2-tick and 5-tick stabilates, respectively. A total of 30 treated calves reacted mildly or not at all. Both the treated and untreated, recovered calves resisted completely the challenge infection which killed 3 of 4 susceptible controls. The effect of 1 dose of long-acting oxytetracycline was equal to that of 8 daily treatments with chlortetracycline; 2 doses of the oxytetracycline suppressed almost all clinical responses at immunisation.     

Induction of parturition with prostaglandin F2α in cows with hydrallantois. A case report

Two cows with hydrallantois were treated with single intramuscular injection of 30 mg (cow number 1) and 25 mg (cow number 2) prostaglandin F_2α (PGF_2α). At about 82 hours post-injection, most of the fluids were expelled and a dead calf was delivered by forced extraction from cow number 1. Cow number 2 delivered twin calves (1 live, 1 dead) without assistance. The cow lost 225 Kg body weight (162.7 Kg fluid and 62.2 Kg weight of fetuses). Plasma progesterone was 4.45 ng/ml before PGF_2α injection and 0.79 ng/ml 24 hours post-injection. No abnormal lesions or pathogens were found at necropsy of the dead calves. Fetal membranes were retained in both cows and were removed manually four days post-calving.     

The influence of antibiotics on experimental moniliasis

Summary The effects of the intraperitoneal administration of oxytetracycline and chlortetracycline on mice of strain CBA each inoculated by the same route with 6 million cells ofCandida albicans were assessed primarily on the basis of histological examination. An injection of oxytetracycline given at a dosage of 2.5 mg two hours after fungal inoculation, and repeated 24 hours later, resulted in the appearance of enhanced forms of systemic infection as indicated by early mortality. Enhancement of infection was referred to two forms:—1. Degenerative enhancement determined the deaths of some animals following the appearance of cloudy swelling in the cellular elements of the heart and kidneys, and was not related to the degree of fungal colonisation, which was frequently meagre or occasionally absent.2. Colonial enhancement was regarded as involving a rapid colonisation of the tissues of the heart and kidneys by a pseudomycelial growth form of the fungus. In this type of infection, histological evidence of an impairment of leucocytic function in the host was obtained.Inoculated mice, previously treated with oxytetracycline or chlortetracycline (both at dosages of 2.5 mg) and variously treated 2 to 72 hours later with these antibiotics, gave no evidence of enhancement of infection. Both antibiotics, however, contributed to an increase in regional infection within the peritoneal cavity. Multiple regional infection was increased by 60% by the use of oxytetracycline, and by 50% by the use of chlortetracycline. The percentage of systemic disease reactions rose in inoculated animals receiving oxytetracycline: it fell significantly where chlortetracycline had been employed, denoting the existence of protection from systemic infection.Both enhancement of and protection from infection were viewed as manifestations of the modification of a basic, systemic mechanism of host defence.     

Leishmania donovani: Oral efficacy and toxicity of formycin B in the infected hamster

Formycin B, a structural analog of inosine, was evaluated as an orally administrable antileishmanial agent. Against Leishmania donovani in hamsters, it achieved an 85–92% reduction in numbers of parasites in livers of infected animals after oral administration at 13 mg/kg/day for 4 days. Its efficacy by oral administration was approximately four to eight times that by intramuscular administration and four times that of the positive control drug Glucantime by intramuscular administration. The levels of formycin B in serum after the final oral administration of 26 mg/kg/day were 1.4 μg/ml at 1 hr and 0.3 μg/ml at 2 hr. The concentration in liver was greater (9.0 μg/ml at 1 hr) and declined more slowly. With this latter dosage or with 104 mg/kg/day there was no acute toxicity of formycin B to bone marrow or formed elements of the blood. The only statistically significant toxicity to the liver was a doubling of serum total bilirubin levels. Comparison of the in vivo efficacy of formycin B against L. donovani to the mild acute toxicity of the drug suggests that formycin B has potential as an oral agent against visceral leishmaniasis.     

Cefonicid as Therapy for Uncomplicated Gonococcal Urethritis Caused by Penicillinase-Producing Neisseria gonorrhoeae

Young men with uncomplicated gonococcal urethritis were treated with 1 gram of cefonicid given intramuscularly plus 1 gram of probenecid by mouth. Of 53 evaluable patients, 33 (62%) had penicillinase-producing Neisseria gonorrhoeae. All but one of these patients were cured. All men who had penicillin-sensitive infections were cured. Cefonicid was highly effective in the treatment of both penicillin-sensitive and penicillin-resistant N gonorrhoeae. Other than moderate pain at the site of injection, there were no adverse side effects. Cefonicid can be added to the group of newer cephalosporins that are effective in the treatment of gonococcal urethritis caused by either penicillin-sensitive or penicillin-resistant strains.     

Effect of the extract made from Cochinchina momordica seeds on the humoral immune responses of mice to a commercial foot-and-mouth disease vaccine (serotypes O and Asia 1)

The extract from ECMS was investigated for its effect on the humoral immune responses to foot-and-mouth disease vaccination. Fifty-six mice were randomly divided into seven groups with eight animals in each. Mice in groups 5 to 7 were subcutaneously (s.c.) injected with 0.5 mg DEX daily for 4 days to induce immunosuppression. The animals were then orally given ECMS (200 μg in 250 μl saline) in groups 3 and 6 or 250 μl saline in group 2, or s.c. injected with ECMS (50 μg in 100 μl saline) in groups 4 and 7 or 100 μl saline in group 5. After that, the animals in groups 2 to 7 were s.c. immunized twice with 100 μl of commercial oil-adjuvanted bivalent FMDV vaccine (serotypes O and Asia 1) at intervals of 21 days. Mice in group 1 received injection of 100 μl saline only. After 2 weeks, blood was sampled to determine FMDV-specific IgG and isotype IgG1, IgG2a, IgG2b and IgG3. Results indicated that oral administration or s.c. injection of ECMS augmented responses of specific IgG and most IgG isotypes. Giving ECMS tended to enhance serum-specific IgG and IgG isotype responses of mice immunosuppressed by s.c. injection of DEX. Considering the safety and immunomodulatory effect of ECMS in both normal and immunosuppressed mice demonstrated in the present study, this extract deserves further investigation to evaluate its potential in improving FMD vaccination in farm animals such as pigs, sheep and cattle.